Why the study?
PDE4B is critically involved in neutrophil inflammation and microvascular obstruction leading to myocardial ischemia/reperfusion injury, and its selective inhibition might protect cardiac function.
Does selective inhibition of PDE4B protect cardiac function in patients with acute myocardial infarction designated for reperfusion therapy?
Does selective inhibition of PDE4B protect cardiac function in patients with acute myocardial infarction designated for reperfusion therapy?
Selective inhibition of PDE4B is proposed as a potential therapeutic target to reduce neutrophil inflammation and microvascular obstruction in acute myocardial infarction.
PDE4B inhibition merits evaluation in AMI reperfusion trials; extends RCT neutrophil data to microvascular outcomes.
PDE4B is critically involved in neutrophil inflammation and microvascular obstruction, leading to MI/R injury. Selective inhibition of PDE4B might protect cardiac function in patients with acute myocardial infarction designated for reperfusion therapy.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: